Answers are grounded in this paper and cite their sources.
Shows ACD137 reduces pain and inflammation in chemotherapy-induced peripheral neuropathy and osteoarthritis, indicating potential therapeutic benefits.
OBJECTIVES: . METHODS: We have identified ACD137 as a potent and selective negative allosteric modulator (NAM) of TrkA during a lead optimization program. The potency of ACD137 on TrkA and selectivity over TrkB was determined in cell-based assays. ACD137 was tested for its analgesic and anti-inflammatory effects in a model of chemotherapy induced peripheral neuropathy (CIPN) using paclitaxel and in the mono-iodo acetate (MIA)-induced osteoarthritis model in rats. After oral administration in rats, ACD137 reduced mechanical allodynia in the CIPN model in a dose-dependent manner with maximal analgesic efficacy similar to the effect of gabapentin. In a comparative arthritis study using the anti-NGF antibody tanezumab as comparator, ACD137 reduced both evoked and non-evoked pain behavior as well as inflammation with similar efficacy as tanezumab. Surprisingly, ACD137 demonstrated a significant protective effect against knee joint deterioration, something that was not observed with tanezumab. CONCLUSIONS: active negative allosteric modulator of TrkA exhibiting analgesic effects in models of neuropathic and nociceptive pain. The molecule possesses promising properties for further pre-clinical development.
No takes yet. Share an insight, caveat, or question.
Forsell et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: